Clinical Trial Update: Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant and adjuvant trial evaluating ribociclib with endocrine therapy for clinically high-risk ER-positive, HER2-negative breast cancer is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• KISQALI (ribociclib)

Snippet

Sponsor: SOLTI Breast Cancer Research Group | Conditions: Breast Cancer Stage II | Phase 2 | Status: RECRUITING